Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
ZUG, Switzerland, April 04, 2024 -- Pharvaris , a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema attacks,...
John Anderson Consortium Of Independent Immunology Clinics Independent Immunology Clinics Early Onset Response Hereditary Angioedema Digital Abstract Display
Source: marketscreener.com